Abstract: The present application provides a composition for inducing chondrogenesis comprising an Wnt antagonist and a pharmaceutically acceptable carrier. The present application also provides a method for inducing chondrogenesis comprising administering an Wnt antagonist and a pharmaceutically acceptable carrier to a subject. The present application further provides a method for treating a cartilage-related disease comprising administering a therapeutically effective amount of an Wnt antagonist and a pharmaceutically acceptable carrier to a subject.

Abstract: The present invention provides a biomembrane phase-change droplet (PCD), including a hydrophobic liquid core; and a phospholipid-containing biomembrane encapsulating the hydrophobic liquid core, wherein the hydrophobic liquid core is vaporized by ultrasonic irradiation. The present disclosure also provides a drug carrier, including a biomembrane phase-change droplet; and a hydrophobic drug embedded on the biomembrane of the biomembrane phase-change droplet, wherein the hydrophobic drug is presented in an amount of 1-10 wt %, based on the weight of the drug carrier. The present invention further provides the use of aforementioned biomembrane phase-change droplet (PCD) and drug carrier.